ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,777.50
4.00 (0.23%)
Last Updated: 10:42:46
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.00 0.23% 1,777.50 1,777.50 1,778.00 1,781.00 1,771.50 1,780.00 847,325 10:42:46
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.87 73.28B

GlaxoSmithKline PLC Annual Report 2014 on Form 20-F (1809G)

02/03/2015 1:30pm

UK Regulatory


Gsk (LSE:GSK)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Gsk Charts.

TIDMGSK

RNS Number : 1809G

GlaxoSmithKline PLC

02 March 2015

GlaxoSmithKline plc

Annual Report 2014 on Form 20-F

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 27 February 2015 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2014. GSK's Annual Report 2014 on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk.

A hard copy version of the Annual Report 2014, together with the Annual Summary and Notice of Annual General Meeting will be available on or about 25 March 2015

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2014, free of charge, by either:

(i) writing to Equiniti, our registrars in the UK, at the following address: Equiniti, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0871 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);

(ii) writing to The Bank of New York Mellon, our ADR depositary in the US, at the following address: BNY Mellon Depositary Receipts, PO Box 30170, College Station, Texas, TX 77842-3170, or by telephone on 1877 3531154 (US toll free); or

   (iii)      contacting the GSK Response Center in the USA at 1888-825-5249 (US toll free). 

Victoria Whyte

Company Secretary

2 March 2015

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSJTMFTMBIMMRA

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock